Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.39 |
| ▸ | TNF | P01375 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | DRD3 | P35462 | 2/20 | 0.33 |
| ▸ | CCR8 | P51685 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31146936 | 1.00 | AHR (0.42) | AHRPRKCITNFRIPK1PARP1 | |
| SCHEMBL620047 | 0.83 | TNF (0.39) | AHRPRKCITNFRIPK1PARP1 | |
| SCHEMBL29445672 | 0.81 | TNF (0.45) | TNFRIPK1PARP1GPR84CCR8 | |
| SCHEMBL2124264 | 0.81 | AHR (0.48) | AHRPRKCIPARP1DRD4DRD3 | |
| SCHEMBL2542070 | 0.81 | TNF (0.45) | TNFRIPK1PARP1GPR84CCR8 | |
| SCHEMBL29556631 | 0.81 | AHR (0.48) | AHRPRKCIPARP1DRD4DRD3 | |
| SCHEMBL10180118 | 0.75 | P2RX7 (0.38) | AHRPRKCITNFRIPK1PARP1 | |
| SCHEMBL16004965 | 0.75 | AHR (0.35) | AHRPRKCITNFRIPK1PARP1 | |
| SCHEMBL30144058 | 0.75 | AHR (0.35) | AHRPRKCITNFRIPK1PARP1 | |
| SCHEMBL806287 | 0.74 | TNF (0.39) | PRKCITNFRIPK1PARP1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119161324-A | Methods and compounds for restoring mutant p53 function | 皮姆维制药公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-117440953-A | Substituted bicyclic heteroaryl compounds as KRAS G12D inhibitors | 苏州浦合医药科技有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-111954525-B | Prodrugs of fused bicyclic C5aR antagonists | 凯莫森特里克斯股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | CHEMOCENTRYX, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2023104018-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUND AS KRAS G12D INHIBITOR | 苏州浦合医药科技有限公司 | 2023-06-15 | — | — | WO | disclosed |
| WO-2023104018-A1 | SUBSTITUTED BICYCLIC HETEROARYL COMPOUND AS KRAS G12D INHIBITOR | 苏州浦合医药科技有限公司 | 2023-06-15 | — | — | WO | disclosed |
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | CHEMOCENTRYX, INC. | 2023-05-18 | — | — | US | disclosed |
| EP-1951684-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | Targegen, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| WO-2008037626-A1 | QUINOLINE DERIVATIVES WITH 5-HT-BINDING PROPERTIES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-04-03 | — | — | WO | disclosed |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2008-04-03 | — | — | US | disclosed |
| WO-2008008059-A1 | ANTI-CANCER AGENTS ANS USES THEREOF | LOCUS PHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007056075-A2 | SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | LOCUS PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151002-A1 | 6-5 FUSED RINGS AS C5a INHIBITORS | C5AR1, C5AR2, C3AR1 | AHR 2160/4885PRKCI 3753/4885TNF 715/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | AHR 349/4885PRKCI 803/4885TNF 2513/4885 |
| US-11773091-B2 | 6-5 fused rings as C5a inhibitors | C5AR1, C5AR2, C3AR1 | AHR 2160/4885PRKCI 3753/4885TNF 715/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | AHR 349/4885PRKCI 803/4885TNF 2513/4885 |
| US-20060270686-A1 | Anti-cancer agents and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, CBR3 | AHR 332/4885PRKCI 4434/4885TNF 4806/4885 |
| US-20080081907-A1 | 2-AMINOQUINOLINE DERIVATIVES | AR, ADRA2C, RCC2 | AHR 127/4885PRKCI 4701/4885TNF 4876/4885 |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | AHR 162/4885PRKCI 210/4885TNF 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.